A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now ...

For decades after the identification of mpox in humans in the Democratic Republic of Congo (DRC) in 1970, the disease was largely confined to the rural areas of Central and West Africa and thus ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Rifampin-resistant tuberculosis has traditionally been treated with 18-to-24-month regimens, but shorter, all-oral regimens may offer efficacious alternatives. New research findings are summarized ...

Supported in part by grants (JP18K09018, to Dr. Ito, and 21H05046, to Dr. Takayanagi) from the Japan Society for the Promotion of Science KAKENHI program, by a grant (JPMJFR205Z, to Dr. Okamoto ...

Two patients with congenital generalized lipodystrophy type 1 due to a variant in AGPAT2 (c.589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were ...

Daniel Aaron is an associate professor of law at the University of Utah S.J. Quinney College of Law. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.

To the Editor: The results of the SENIOR-RITA (Older Patients with Non–ST-Segment Elevation Myocardial Infarction Randomized Interventional Treatment) trial by Kunadian et al. (Nov. 7 issue) 1 ...

Mpox has been endemic in remote, rural areas of Africa for decades but has attracted relatively little attention until the global outbreak that began in 2022. In July of that year, I declared a ...